How does the AJCC 8th edition differ from earlier editions in staging?

How does the AJCC 8th edition differ from earlier editions in staging?

• A. Eliminates biomarker data and simplifies staging to size only.
• B. Uses only imaging results; excludes pathology.
• C. Introduces site-specific prognostic groupings and updated criteria; sometimes incorporates biomarkers; more precise definitions for T/N/M.
• D. Replaces TNM with a three-digit code.

Answer: (C)

The main idea being tested is that the AJCC 8th edition adds site-specific prognostic groupings and biomarker information into staging, while refining the definitions of T, N, and M. This edition keeps the TNM framework but makes staging more nuanced by incorporating tumor biology for certain cancers. Because of this, two tumors with the same size and extent (same T/N/M) can have different prognostic stage groups if their biomarker profiles differ, leading to more accurate prognosis and more tailored treatment guidance. For example, in breast cancer, receptor status (ER/PR/HER2) and other biomarkers influence the prognostic stage, not merely the anatomic factors. It’s not a simplification to size only, nor is it based on imaging alone, and it doesn’t replace TNM with a three-digit code. Instead, it expands staging with site-specific prognostic factors and updated criteria to reflect biology and more precise definitions of tumor extent.

The main idea being tested is that the AJCC 8th edition adds site-specific prognostic groupings and biomarker information into staging, while refining the definitions of T, N, and M. This edition keeps the TNM framework but makes staging more nuanced by incorporating tumor biology for certain cancers. Because of this, two tumors with the same size and extent (same T/N/M) can have different prognostic stage groups if their biomarker profiles differ, leading to more accurate prognosis and more tailored treatment guidance. For example, in breast cancer, receptor status (ER/PR/HER2) and other biomarkers influence the prognostic stage, not merely the anatomic factors.

It’s not a simplification to size only, nor is it based on imaging alone, and it doesn’t replace TNM with a three-digit code. Instead, it expands staging with site-specific prognostic factors and updated criteria to reflect biology and more precise definitions of tumor extent.